Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Arch. argent. pediatr ; 116(6): 744-748, dic. 2018. ilus
Artigo em Espanhol | LILACS-Express | ID: biblio-973689

RESUMO

La enfermedad granulomatosa crónica es una inmunodeficiencia primaria infrecuente, debida a un defecto en la actividad microbicida de los fagocitos, originada por mutaciones en los genes que codifican alguna de las subunidades del complejo enzimático nicotinamida adenina dinucleótido fosfato oxidasa. La incidencia estimada es 1 en 250 000 recién nacidos vivos. Puede presentarse desde la infancia hasta la adultez, por lo general, en menores de 2 años. Las infecciones bacterianas y fúngicas, en conjunto con las lesiones granulomatosas, son las manifestaciones más habituales de la enfermedad. Los microorganismos aislados más frecuentemente son Aspergillus spp., Staphylococcus aureus, Serratia marcescens, Nocardia spp. Se reporta el caso clínico de un varón de 1 año de vida en el que se diagnosticó enfermedad granulomatosa crónica a partir de infecciones múltiples que ocurrieron simultáneamente: aspergilosis pulmonar invasiva, osteomielitis por Serratia marcescens y granuloma cervical por Enterobacter cloacae.


Chronic granulomatous disease is an uncommon primary immunodeficiency due to a defect of the killing activity of phagocytes, caused by mutations in any of the genes encoding subunits of the superoxide-generating phagocyte NADPH oxidase system. The incidence is 1 in 250 000 live births. It can occur from infancy to adulthood, usually in children under 2 years. Bacterial and fungal infections in association with granuloma lesions are the most common manifestations of the disease. Aspergillus species, Staphylococcus aureus, Serratia marcescens, Nocardia species are the most common microorganisms isolated. We describe here a case of a 1-year-old boy with chronic granulomatous disease and invasive pulmonary aspergillosis, Serratia marcescens osteomyelitis and Enterobacter cloacae cervical granuloma.

2.
Arch Argent Pediatr ; 116(6): e744-e748, 2018 Dec 01.
Artigo em Espanhol | MEDLINE | ID: mdl-30457728

RESUMO

Chronic granulomatous disease is an uncommon primary immunodeficiency due to a defect of the killing activity of phagocytes, caused by mutations in any of the genes encoding subunits of the superoxide-generating phagocyte NADPH oxidase system. The incidence is 1 in 250 000 live births. It can occur from infancy to adulthood, usually in children under 2 years. Bacterial and fungal infections in association with granuloma lesions are the most common manifestations of the disease. Aspergillus species, Staphylococcus aureus, Serratia marcescens, Nocardia species are the most common microorganisms isolated. We describe here a case of a 1-year-old boy with chronic granulomatous disease and invasive pulmonary aspergillosis, Serratia marcescens osteomyelitis and Enterobacter cloacae cervical granuloma.

4.
J Allergy Clin Immunol ; 138(1): 241-248.e3, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-26936803

RESUMO

BACKGROUND: Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by inborn errors of the phagocyte nicotinamide adenine dinucleotide phosphate oxidase complex. From the first year of life onward, most affected patients display multiple, severe, and recurrent infections caused by bacteria and fungi. Mycobacterial infections have also been reported in some patients. OBJECTIVE: Our objective was to assess the effect of mycobacterial disease in patients with CGD. METHODS: We analyzed retrospectively the clinical features of mycobacterial disease in 71 patients with CGD. Tuberculosis and BCG disease were diagnosed on the basis of microbiological, pathological, and/or clinical criteria. RESULTS: Thirty-one (44%) patients had tuberculosis, and 53 (75%) presented with adverse effects of BCG vaccination; 13 (18%) had both tuberculosis and BCG infections. None of these patients displayed clinical disease caused by environmental mycobacteria, Mycobacterium leprae, or Mycobacterium ulcerans. Most patients (76%) also had other pyogenic and fungal infections, but 24% presented solely with mycobacterial disease. Most patients presented a single localized episode of mycobacterial disease (37%), but recurrence (18%), disseminated disease (27%), and even death (18%) were also observed. One common feature in these patients was an early age at presentation for BCG disease. Mycobacterial disease was the first clinical manifestation of CGD in 60% of these patients. CONCLUSION: Mycobacterial disease is relatively common in patients with CGD living in countries in which tuberculosis is endemic, BCG vaccine is mandatory, or both. Adverse reactions to BCG and severe forms of tuberculosis should lead to a suspicion of CGD. BCG vaccine is contraindicated in patients with CGD.


Assuntos
Doença Granulomatosa Crônica/complicações , Infecções por Mycobacterium/diagnóstico , Infecções por Mycobacterium/etiologia , Vacina BCG/administração & dosagem , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/epidemiologia , Infecções Bacterianas/etiologia , Infecções Bacterianas/mortalidade , Criança , Pré-Escolar , Feminino , Doença Granulomatosa Crônica/epidemiologia , Doença Granulomatosa Crônica/mortalidade , Doença Granulomatosa Crônica/terapia , Humanos , Lactente , Masculino , Infecções por Mycobacterium/epidemiologia , Infecções por Mycobacterium/mortalidade , Micoses/diagnóstico , Micoses/epidemiologia , Micoses/etiologia , Micoses/mortalidade , Avaliação de Resultados da Assistência ao Paciente , Estudos Retrospectivos , Tuberculose/diagnóstico , Tuberculose/etiologia
5.
Pediatr Blood Cancer ; 62(12): 2101-7, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26185101

RESUMO

AIM: We analyzed data from 71 patients with chronic granulomatous disease (CGD) with a confirmed genetic diagnosis, registered in the online Latin American Society of Primary Immunodeficiencies (LASID) database. RESULTS: Latin American CGD patients presented with recurrent and severe infections caused by several organisms. The mean age at disease onset was 23.9 months, and the mean age at CGD diagnosis was 52.7 months. Recurrent pneumonia was the most frequent clinical condition (76.8%), followed by lymphadenopathy (59.4%), granulomata (49.3%), skin infections (42%), chronic diarrhea (41.9%), otitis (29%), sepsis (23.2%), abscesses (21.7%), recurrent urinary tract infection (20.3%), and osteomyelitis (15.9%). Adverse reactions to bacillus Calmette-Guérin (BCG) vaccination were identified in 30% of the studied Latin American CGD cases. The genetic diagnoses of the 71 patients revealed 53 patients from 47 families with heterogeneous mutations in the CYBB gene (five novel mutations: p.W361G, p.C282X, p.W483R, p.R226X, and p.Q93X), 16 patients with the common deletion c.75_76 del.GT in exon 2 of NCF1 gene, and two patients with mutations in the CYBA gene. CONCLUSION: The majority of Latin American CGD patients carry a hemizygous mutation in the CYBB gene. They also presented a wide range of clinical manifestations most frequently bacterial and fungal infections of the respiratory tract, skin, and lymph nodes. Thirty percent of the Latin American CGD patients presented adverse reactions to BCG, indicating that this vaccine should be avoided in these patients.


Assuntos
Doença Granulomatosa Crônica , Glicoproteínas de Membrana/genética , Mutação , NADPH Oxidases/genética , Sistema de Registros , Abscesso/epidemiologia , Abscesso/etiologia , Abscesso/genética , Adolescente , Idade de Início , Criança , Pré-Escolar , Diarreia/epidemiologia , Diarreia/etiologia , Diarreia/genética , Feminino , Doença Granulomatosa Crônica/complicações , Doença Granulomatosa Crônica/epidemiologia , Doença Granulomatosa Crônica/genética , Hispano-Americanos , Humanos , Lactente , Recém-Nascido , Doenças Linfáticas/epidemiologia , Doenças Linfáticas/etiologia , Doenças Linfáticas/genética , Masculino , NADPH Oxidase 2 , Osteomielite/epidemiologia , Osteomielite/etiologia , Osteomielite/genética , Otite/epidemiologia , Otite/etiologia , Otite/genética , Pneumonia/epidemiologia , Pneumonia/etiologia , Pneumonia/genética , Sepse/epidemiologia , Sepse/etiologia , Sepse/genética , Dermatopatias/epidemiologia , Dermatopatias/etiologia , Dermatopatias/genética , Infecções Urinárias/epidemiologia , Infecções Urinárias/etiologia , Infecções Urinárias/genética
6.
J Allergy Clin Immunol ; 135(4): 988-97.e6, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25595268

RESUMO

BACKGROUND: Common variable immunodeficiency (CVID) is usually well controlled with immunoglobulin substitution and immunomodulatory drugs. A subgroup of patients has a complicated disease course with high mortality. For these patients, investigation of more invasive, potentially curative treatments, such as allogeneic hematopoietic stem cell transplantation (HSCT), is warranted. OBJECTIVE: We sought to define the outcomes of HSCT for patients with CVID. METHODS: Retrospective data were collected from 14 centers worldwide on patients with CVID receiving HSCT between 1993 and 2012. RESULTS: Twenty-five patients with CVID, which was defined according to international criteria, aged 8 to 50 years at the time of transplantation were included in the study. The indication for HSCT was immunologic dysregulation in the majority of patients. The overall survival rate was 48%, and the survival rate for patients undergoing transplantation for lymphoma was 83%. The major causes of death were treatment-refractory graft-versus-host disease accompanied by poor immune reconstitution and infectious complications. Immunoglobulin substitution was stopped in 50% of surviving patients. In 92% of surviving patients, the condition constituting the indication for HSCT resolved. CONCLUSION: This multicenter study demonstrated that HSCT in patients with CVID was beneficial in most surviving patients; however, there was a high mortality associated with the procedure. Therefore this therapeutic approach should only be considered in carefully selected patients in whom there has been extensive characterization of the immunologic and/or genetic defect underlying the CVID diagnosis. Criteria for patient selection, refinement of the transplantation protocol, and timing are needed for an improved outcome.


Assuntos
Imunodeficiência de Variável Comum/terapia , Transplante de Células-Tronco Hematopoéticas , Células-Tronco Hematopoéticas , Adolescente , Adulto , Causas de Morte , Criança , Imunodeficiência de Variável Comum/complicações , Imunodeficiência de Variável Comum/mortalidade , Feminino , Seguimentos , Sobrevivência de Enxerto , Doença Enxerto-Hospedeiro/etiologia , Doença Enxerto-Hospedeiro/prevenção & controle , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Condicionamento Pré-Transplante , Resultado do Tratamento , Adulto Jovem
7.
Arch. argent. pediatr ; 112(6): e247-e251, dic. 2014. tab
Artigo em Espanhol | LILACS-Express | ID: lil-734314

RESUMO

La falla de respuesta anticorpórea frente a antígenos polisacáridos es una inmunodeficiencia primaria humoral definida como una pobre respuesta frente a antígenos polisacáridos contenidos en la vacuna antineumocócica de 23 serotipos, con inmunoglobulinas normales y respuesta adecuada frente a antígenos proteicos. Las manifestaciones clínicas reportadas incluyen infecciones sinopulmonares recurrentes, infecciones sistémicas y asma. El objetivo de esta presentación es describir las manifestaciones clínicas y la evolución en una cohorte de pacientes con falla de respuesta anticorpórea frente a antígenos polisacáridos diagnosticados y seguidos en nuestro centro entre 1998 y 2012.


Specific antibody deficiency is a common antibody immunodeficiency defined as a poor antibody response to pneumococcal polysaccharides antigens present in the 23-valent pneumococcal vaccine, with normal immunoglobulins and normal response to protein antigens. Clinical manifestations include recurrent sinopulmonary infections, severe infections and asthma. The aim of this presentation is to describe clinical manifestations and evolution of a cohort of children with specific antibody deficiency diagnosed and followed in our center between 1998 and 2012.

8.
Arch. argent. pediatr ; 112(6): e247-e251, dic. 2014. tab
Artigo em Espanhol | BINACIS | ID: bin-131513

RESUMO

La falla de respuesta anticorpórea frente a antígenos polisacáridos es una inmunodeficiencia primaria humoral definida como una pobre respuesta frente a antígenos polisacáridos contenidos en la vacuna antineumocócica de 23 serotipos, con inmunoglobulinas normales y respuesta adecuada frente a antígenos proteicos. Las manifestaciones clínicas reportadas incluyen infecciones sinopulmonares recurrentes, infecciones sistémicas y asma. El objetivo de esta presentación es describir las manifestaciones clínicas y la evolución en una cohorte de pacientes con falla de respuesta anticorpórea frente a antígenos polisacáridos diagnosticados y seguidos en nuestro centro entre 1998 y 2012.(AU)


Specific antibody deficiency is a common antibody immunodeficiency defined as a poor antibody response to pneumococcal polysaccharides antigens present in the 23-valent pneumococcal vaccine, with normal immunoglobulins and normal response to protein antigens. Clinical manifestations include recurrent sinopulmonary infections, severe infections and asthma. The aim of this presentation is to describe clinical manifestations and evolution of a cohort of children with specific antibody deficiency diagnosed and followed in our center between 1998 and 2012.(AU)

9.
Arch Argent Pediatr ; 112(6): e247-51, 2014 Dec.
Artigo em Espanhol | MEDLINE | ID: mdl-25362922

RESUMO

Specific antibody deficiency is a common antibody immunodeficiency defined as a poor antibody response to pneumococcal polysaccharides antigens present in the 23-valent pneumococcal vaccine, with normal immunoglobulins and normal response to protein antigens. Clinical manifestations include recurrent sinopulmonary infections, severe infections and asthma. The aim of this presentation is to describe clinical manifestations and evolution of a cohort of children with specific antibody deficiency diagnosed and followed in our center between 1998 and 2012.


Assuntos
Síndromes de Imunodeficiência/diagnóstico , Polissacarídeos Bacterianos/imunologia , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino
10.
Arch. argent. pediatr ; 112(6): e247-51, 2014 Dec.
Artigo em Espanhol | BINACIS | ID: bin-133384

RESUMO

Specific antibody deficiency is a common antibody immunodeficiency defined as a poor antibody response to pneumococcal polysaccharides antigens present in the 23-valent pneumococcal vaccine, with normal immunoglobulins and normal response to protein antigens. Clinical manifestations include recurrent sinopulmonary infections, severe infections and asthma. The aim of this presentation is to describe clinical manifestations and evolution of a cohort of children with specific antibody deficiency diagnosed and followed in our center between 1998 and 2012.

12.
J Clin Immunol ; 33(7): 1216-22, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23846854

RESUMO

PURPOSE: Several studies have shown that subcutaneous immunoglobulin (SCIG) infusions demonstrate similar efficacy to intravenous Ig (IVIG) in preventing infections in patients with primary immunodeficiency diseases (PID), and are safe and well tolerated in this population. This open, prospective/retrospective, multicenter study was designed to compare the effectiveness, safety and tolerability of a 16 % liquid human IgG preparation (Beriglobina P), administered SC, with previous IVIG treatment in PID pediatric patients in Argentina. METHODS: Fifteen subjects were enrolled in the study, and a total of 13 subjects (aged 6-18 years) completed the 36-week SCIG treatment period. All children had previously received IVIG treatment. The dose of SCIG equaled the previous IVIG dose and subjects received an average weekly dose of 139 mg/kg (range 105-181) during the SCIG period. RESULTS: Significantly higher serum IgG trough levels were recorded on SCIG treatment at 16, 24, and 36 weeks, when compared with previous IgG trough levels on steady-state IVIG treatment. The annualized infection rate was 1.4 infections/subject/year during the IVIG administration period compared with 0.4 infections/subject/year during the SCIG period. All subjects who completed the study chose to continue administering SCIG at home after the study had ended. CONCLUSIONS: These data confirm that self-administered SCIG therapy is a well-tolerated and effective alternative to IVIG therapy for children with PID.


Assuntos
Imunoglobulina G/administração & dosagem , Imunoglobulinas Intravenosas/administração & dosagem , Síndromes de Imunodeficiência/terapia , Imunoterapia/métodos , Infecção/terapia , Adolescente , Argentina , Criança , Estudos de Viabilidade , Feminino , Humanos , Imunoglobulina G/sangue , Síndromes de Imunodeficiência/complicações , Síndromes de Imunodeficiência/epidemiologia , Síndromes de Imunodeficiência/imunologia , Infecção/epidemiologia , Infecção/imunologia , Injeções Subcutâneas , Masculino , Estudos Prospectivos
15.
Arch. argent. pediatr ; 105(6): 532-535, dic.2007.
Artigo em Espanhol | LILACS | ID: lil-478475

RESUMO

Las infecciones son una de las causas más frecuentes de consulta ambulatoria y de hospitalización en niños. En ocasiones, debido a la gravedad o la reiteración de episodios, se plantea en la práctica diaria la conveniencia de realizar estudios para verificar la inmunocompetencia de estos pacientes. Cuando estos episodios que amenazan la vida se reiteran, la indicación de estudios sobre la inmunidad es universalmente aceptada. En el primer episodio, sin embargo, la necesidad de efectuarlos puede resultar polémica. Al respecto, el punto de vista prevalente aconseja estudios especializados en niños que hayan presentado al menos dos de estos episodios, decisión que conlleva un riesgo cierto de subdiagnóstico y puede dar lugar a un ulterior episodio de infección potencialmente mortal y eventualmente prevenible. Se presentan tres pacientes afectados de distintas inmunodeficiencias caracterizadas por exhibir, a veces como primera manifestación, infecciones bacterianas sistémicas. Se plantean los estudios iniciales a solicitar, para descartar defectos inmunológicos subyacentes en este tipo de pacientes, y se discute la eventual conveniencia de realizarlos luego del primer episodio de infección bacteriana sistémica.


Infection is one of the most frequent causes of disease in children. Pediatricians are frequently faced to ambulatory or hospitalised children with infection. Sometimes, the severity or frequency of the episodes raises concern about the convenience of performing immunological studies. When these life threatening, bacterial systemic infections are repeated, immunological studies are mandatory. Two or more such episodes are required by most authors to alert the physician to possible immunodeficiency. However, in immunodeficiencies, a second potentially severe and even fatal episode of infection may be the consequence of that policy. We show here three cases of primary immunodeficiencies presenting with systemic severe bacterial infections, and we discuss the immunological tests to be initially performed and the convenience of doing so after a first episode of systemic bacterial infection.


Assuntos
Criança , Infecções Bacterianas , Imunocompetência , Fatores Imunológicos , Amoxicilina
16.
Arch. argent. pediatr ; 105(6): 532-535, dic.2007.
Artigo em Espanhol | BINACIS | ID: bin-122495

RESUMO

Las infecciones son una de las causas más frecuentes de consulta ambulatoria y de hospitalización en niños. En ocasiones, debido a la gravedad o la reiteración de episodios, se plantea en la práctica diaria la conveniencia de realizar estudios para verificar la inmunocompetencia de estos pacientes. Cuando estos episodios que amenazan la vida se reiteran, la indicación de estudios sobre la inmunidad es universalmente aceptada. En el primer episodio, sin embargo, la necesidad de efectuarlos puede resultar polémica. Al respecto, el punto de vista prevalente aconseja estudios especializados en niños que hayan presentado al menos dos de estos episodios, decisión que conlleva un riesgo cierto de subdiagnóstico y puede dar lugar a un ulterior episodio de infección potencialmente mortal y eventualmente prevenible. Se presentan tres pacientes afectados de distintas inmunodeficiencias caracterizadas por exhibir, a veces como primera manifestación, infecciones bacterianas sistémicas. Se plantean los estudios iniciales a solicitar, para descartar defectos inmunológicos subyacentes en este tipo de pacientes, y se discute la eventual conveniencia de realizarlos luego del primer episodio de infección bacteriana sistémica.(AU)


Infection is one of the most frequent causes of disease in children. Pediatricians are frequently faced to ambulatory or hospitalised children with infection. Sometimes, the severity or frequency of the episodes raises concern about the convenience of performing immunological studies. When these life threatening, bacterial systemic infections are repeated, immunological studies are mandatory. Two or more such episodes are required by most authors to alert the physician to possible immunodeficiency. However, in immunodeficiencies, a second potentially severe and even fatal episode of infection may be the consequence of that policy. We show here three cases of primary immunodeficiencies presenting with systemic severe bacterial infections, and we discuss the immunological tests to be initially performed and the convenience of doing so after a first episode of systemic bacterial infection.(AU)


Assuntos
Criança , Fatores Imunológicos , Infecções Bacterianas , Imunocompetência , Amoxicilina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA